Targeted cancer drugs that block key kinases for AML and TNBC
Official title: 3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors
Funded at University of Notre Dame · NIH-11359718 · Data updated 2026-11-12
Researchers are developing new, single-step synthesized kinase inhibitors aimed at tackling acute myeloid leukemia and certain tough breast cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project start | May 10, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $445,510 |
| NIH project number | 5R01CA267978-05 |
| Project ID | NIH-11359718 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with acute myeloid leukemia or triple-negative breast cancer, especially those with relapsed or resistant disease, may benefit from later-stage development of these inhibitors.
✕Less likely to help
Patients without AML or TNBC are unlikely to benefit from this specific kinase-targeted approach.
What this research studies
This grant supports work at the University of Notre Dame to create and test novel 3H-pyrazolo[4,3-f]quinoline compounds that can selectively block kinases involved in AML and certain breast cancers. The project focuses on achieving potent activity against FLT3 and CDK family kinases, with attention to overcoming resistance mutations that limit current therapies. The researchers plan to synthesize compounds in a simple one‑flask operation and evaluate their pharmacokinetics to optimize absorption, distribution, metabolism, and excretion. If successful, these compounds could offer new options for patients whose cancers have relapsed or become resistant to existing treatments.
Why it matters
Potential benefit: If successful, patients with AML or certain aggressive breast cancers may have new targeted therapy options that overcome resistance to current treatments.
How similar studies have gone: Prior FLT3 and CDK inhibitors have shown clinical activity, but resistance remains a challenge; this work seeks to extend that success with novel compounds.
Where this research is happening
-
University of Notre Dame
Notre Dame, United States Active
Researchers
- Principal investigator: Sintim, Herman O — University of Notre Dame
- Study coordinator: Sintim, Herman O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.